Features

Kay Parkinson lived the tragedy of seeing both of her children born with an ultra-rare condition, and the elusiveness of accurate diagnosis. She...

As the scientific community eschews scattergun approaches and demand rises for higher-quality, targeted care, Matt Fellows explores how...

2018 has been a year characterised by uncertainty, but also significant leaps in research, access, and industry deals. With 2019 bringing a host...

In November 2018, a Phase 2 clinical trial foundthat 76% of patients who underwent MDMA-assisted psychotherapy no longer had PTSD, twelve months...

Kai Gait, Senior Global Digital Director at GlaxoSmithKline, retraces the steps that have led him to where he is today, and discusses what...

Michael Connellan, Head of External Affairs at the type 1 diabetes charity JDRF, discusses the results of a recent survey which suggests that...

Professor Matthew Hotopf, Director of NIHR Maudsley Biomedical Research Centre, and Professor John R Geddes, Director of NIHR Oxford Health...

“Don’t conform to what people want – take risks. The people who make a big difference are the ones who take risks in uncertain times”

Helena Baker, Vice President of Clinical Strategy at Medical Research Network and a trustee of the newly formed Rare Disease Nurse...

Mistrust of the establishment has fuelled anti-vaccine sentiment in recent years, and adherence has waned as a result. Louis Goss looks into the...